Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APGE Apogee Therapeutics	$36.37 -0.7%	$39.20	$26.20 ▼ $63.50	$1.68B	1.43	728,171 shs	516,521 shs
BEAM Beam Therapeutics	$16.36 -2.9%	$18.73	$13.52 ▼ $35.25	$1.66B	2.22	2.09 million shs	1.90 million shs
IMCR Immunocore	$32.22 -0.1%	$33.33	$23.15 ▼ $39.33	$1.62B	0.77	334,094 shs	210,634 shs
REPL Replimune Group	$5.40 +0.4%	$7.46	$2.68 ▼ $17.00	$421.52M	0.67	3.99 million shs	2.25 million shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APGE Apogee Therapeutics	-3.10%	+0.74%	-3.45%	-0.81%	-24.39%
BEAM Beam Therapeutics	-0.06%	+5.25%	-15.45%	+7.05%	-35.32%
IMCR Immunocore	-1.26%	-1.32%	-4.92%	-11.65%	-10.79%
REPL Replimune Group	-2.71%	-3.93%	+43.47%	-39.75%	-47.77%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APGE Apogee Therapeutics	3.871 of 5 stars	4.4	3.0	0.0	3.1	4.2	0.0
BEAM Beam Therapeutics	2.251 of 5 stars	3.5	0.0	0.0	2.9	2.5	0.6
IMCR Immunocore	1.5929 of 5 stars	3.3	1.0	0.0	1.7	2.5	0.0
REPL Replimune Group	3.9223 of 5 stars	3.1	2.0	4.5	1.8	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APGE Apogee Therapeutics	2.88	Moderate Buy	$97.29	167.82% Upside
BEAM Beam Therapeutics	3.07	Buy	$48.45	195.80% Upside
IMCR Immunocore	2.55	Moderate Buy	$56.89	76.32% Upside
REPL Replimune Group	2.10	Hold	$6.50	20.21% Upside

Current Analyst Ratings Breakdown

Latest REPL, APGE, BEAM, and IMCR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/28/2025	APGE Apogee Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
8/28/2025	APGE Apogee Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$78.00 ➝ $87.00
8/25/2025	IMCR Immunocore	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$48.00
8/14/2025	APGE Apogee Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/11/2025	APGE Apogee Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$90.00
8/6/2025	BEAM Beam Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$25.00 ➝ $21.00
7/30/2025	REPL Replimune Group	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight
7/23/2025	REPL Replimune Group	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight	$17.00 ➝ $3.00
7/23/2025	REPL Replimune Group	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Underperform	$27.00 ➝ $2.00
7/23/2025	REPL Replimune Group	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
7/22/2025	REPL Replimune Group	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APGE Apogee Therapeutics	N/A	N/A	N/A	N/A	$13.43 per share	N/A
BEAM Beam Therapeutics	$60.27M	27.49	N/A	N/A	$10.35 per share	1.58
IMCR Immunocore	$356.15M	4.56	N/A	N/A	$7.71 per share	4.18
REPL Replimune Group	N/A	N/A	N/A	N/A	$4.31 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APGE Apogee Therapeutics	-$182.15M	-$4.13	N/A	N/A	N/A	N/A	-34.65%	-32.76%	11/11/2025 (Estimated)
BEAM Beam Therapeutics	-$376.74M	-$4.50	N/A	N/A	N/A	-661.31%	-43.15%	-31.06%	11/4/2025 (Estimated)
IMCR Immunocore	-$51.09M	-$0.40	N/A	N/A	N/A	-5.70%	-5.40%	-1.93%	11/5/2025 (Estimated)
REPL Replimune Group	-$247.30M	-$3.24	N/A	N/A	N/A	N/A	-69.34%	-52.81%	11/11/2025 (Estimated)

Latest REPL, APGE, BEAM, and IMCR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	APGE Apogee Therapeutics	-$1.03	-$1.13	-$0.10	-$1.13	N/A	N/A
8/7/2025	Q2 2025	IMCR Immunocore	-$0.21	-$0.20	+$0.01	-$0.20	$122.96 million	$130.65 million
8/7/2025	Q1 2026	REPL Replimune Group	-$0.83	-$0.95	-$0.12	-$0.95	$0.50 million	N/A
8/5/2025	Q2 2025	BEAM Beam Therapeutics	-$1.04	-$1.00	+$0.04	-$1.00	$13.29 million	$8.47 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APGE Apogee Therapeutics	N/A	N/A	N/A	N/A	N/A
BEAM Beam Therapeutics	$0.90	5.49%	N/A	N/A	N/A
IMCR Immunocore	N/A	N/A	N/A	N/A	N/A
REPL Replimune Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APGE Apogee Therapeutics	N/A	16.36	16.36
BEAM Beam Therapeutics	N/A	6.75	6.75
IMCR Immunocore	1.01	5.89	5.86
REPL Replimune Group	0.21	6.94	6.94

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APGE Apogee Therapeutics	79.04%
BEAM Beam Therapeutics	99.68%
IMCR Immunocore	84.50%
REPL Replimune Group	92.53%

Insider Ownership

Company	Insider Ownership
APGE Apogee Therapeutics	42.77%
BEAM Beam Therapeutics	3.50%
IMCR Immunocore	10.40%
REPL Replimune Group	5.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APGE Apogee Therapeutics	91	46.11 million	26.39 million	Optionable
BEAM Beam Therapeutics	510	101.16 million	97.62 million	Optionable
IMCR Immunocore	320	50.39 million	45.15 million	Optionable
REPL Replimune Group	210	78.06 million	74.00 million	Optionable

REPL, APGE, BEAM, and IMCR Headlines

Recent News About These Companies

Faruqi & Faruqi Reminds Replimune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 22, 2025 - REPL

August 29 at 11:10 AM | prnewswire.com

REPL Class Action Lawsuit Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Replimune Group, Inc. (REPL) Investors that a Securities Fraud Class Action Lawsuit Has Been Filed

August 29 at 7:56 AM | globenewswire.com

Vanguard Group Inc. Increases Stock Position in Replimune Group, Inc. $REPL

August 29 at 3:14 AM | marketbeat.com

Class Action Filed Against Replimune Group, Inc. (REPL) Seeking Recovery for Investors - Contact Levi & Korsinsky

August 29 at 2:31 AM | theglobeandmail.com

ROSEN, A TOP RANKED LAW FIRM, Encourages Replimune Group, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – REPL

August 28 at 10:31 PM | globenewswire.com

Levi & Korsinsky Notifies Replimune Group, Inc. (REPL) Shareholders of Class Action Lawsuit and September 22, 2025 Deadline

August 28 at 9:30 PM | theglobeandmail.com

REPL Class Action Reminder: Investors with Large Losses Should Contact Robbins LLP for Information About the Pending Lead Plaintiff Deadline in the Replimune Group, Inc. Class Action Lawsuit

August 28 at 8:20 PM | prnewswire.com

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune

August 28 at 8:17 PM | globenewswire.com

Class Action Filed Against Replimune Group, Inc. (REPL) Seeking Recovery for Investors – Contact Levi & Korsinsky

August 28 at 4:42 PM | globenewswire.com

REPL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Replimune Group, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

August 28 at 4:00 PM | globenewswire.com

Investors in Replimune Group, Inc. Should Contact Levi & Korsinsky Before September 22, 2025 to Discuss Your Rights - REPL

August 28 at 11:27 AM | theglobeandmail.com

Replimune Group, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - REPL

August 28 at 8:45 AM | prnewswire.com

Price T Rowe Associates Inc. MD Sells 109,051 Shares of Replimune Group, Inc. $REPL

August 28 at 5:06 AM | marketbeat.com

REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit First Filed by The Rosen Law Firm

August 27 at 5:58 PM | prnewswire.com

September 22, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against REPL

August 27 at 4:29 PM | globenewswire.com

Kirby McInerney LLP Reminds Replimune Group, Inc. Investors of Class Action Filing and Encourages Investors to Contact the Firm

August 27 at 4:19 PM | globenewswire.com

Replimune (REPL) Faces Investor Lawsuit Following 77% Stock Crash After FDA Rejects Key Drug - Hagens Berman

August 27 at 1:20 PM | globenewswire.com

Nuveen LLC Acquires Shares of 671,411 Replimune Group, Inc. $REPL

August 27 at 3:38 AM | marketbeat.com

Replimune Group, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before September 22, 2025 to Discuss Your Rights - REPL

August 26 at 8:46 AM | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - REPL

August 25, 2025 | prnewswire.com

Kessler Topaz Meltzer & Check, LLP Reminds Replimune Group, Inc. Investors of Important Deadline in Securities Fraud Class Action Lawsuit

August 25, 2025 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

REPL, APGE, BEAM, and IMCR Company Descriptions

Apogee Therapeutics NASDAQ:APGE

$36.37 -0.25 (-0.68%)

Closing price 04:00 PM Eastern

Extended Trading

$36.34 -0.02 (-0.07%)

As of 05:41 PM Eastern

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

Beam Therapeutics NASDAQ:BEAM

$16.36 -0.49 (-2.91%)

Closing price 04:00 PM Eastern

Extended Trading

$16.42 +0.07 (+0.40%)

As of 05:47 PM Eastern

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Immunocore NASDAQ:IMCR

$32.22 -0.02 (-0.06%)

Closing price 04:00 PM Eastern

Extended Trading

$32.20 -0.02 (-0.06%)

As of 04:04 PM Eastern

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Replimune Group NASDAQ:REPL

$5.40 +0.02 (+0.37%)

Closing price 04:00 PM Eastern

Extended Trading

$5.40 0.00 (0.00%)

As of 05:50 PM Eastern

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time